On Target is a recurring feature from STAT that dives deep into the most promising drug targets in oncology.
Oncologists may soon have a new immuno-oncology target in their arsenal. Experts expect the Food and Drug Administration to soon approve relatlimab, a Bristol Myers Squibb drug that binds to a cancer target called LAG-3, making it the first new immune checkpoint target in nearly a decade.
Create a display name to comment
This name will appear with your comment